Omalizumab (Xolair) for treatment of asthma

American Family Physician

Volumn 71, Issue 2, 2005, Pages 341-342

  Davydov, Liya ^a,b  

^a LONG ISLAND UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E RECEPTOR; OMALIZUMAB;

ALLERGIC REACTION; ALLERGY; ASTHMA; BASOPHIL; BIOTECHNOLOGY; BRONCHOSPASM; CLINICAL TRIAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; HEADACHE; HUMAN; INJECTION SITE REACTION; MAST CELL; PHARYNGITIS; RECEPTOR BLOCKING; REVIEW; SINUSITIS; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VIRUS INFECTION;

ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; HUMANS;

EID: 12344323523     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (5)

1. Xolair product labeling. Genentech, Inc. Accessed January, 2004, at: http://www.gene.com/gene/common/inc/pi/xolair.jsp.
2. Milgrom H, Fick RB Jr, Su JQ, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. RhuMAb-E25 Study Group. N Engl J Med 1999;341:1966-73.
3. Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH. Anti-IgE for chronic asthma (Cochrane Review). In: The Cochrane Library, Issue 1, 2004. Chichester, UK: John Wiley & Sons, Ltd.
4. Finn A, Gross G, van Bavel J, et al. Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J Allergy Clin Immunol 2003;111:278-84.
5. Corren J, Casale T, Deniz Y, Ashby M. Omalizumab, a recombinant humanized antilgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. J Allergy Clin Immunol 2003;111:87-90.